A new political action group taking on high drug prices has big plans in the works leading up to November’s midterm elections — and a seven-figure budget to make it happen.

David Mitchell, a cancer patient and the former head of a Washington, D.C., public policy firm, last week unveiled the new organization, called Patients for Affordable Drugs NOW. It’s a separate legal entity operating as the political arm of the advocacy group Patients for Affordable Drugs that Mitchell founded last year. Initial funding comes from an entity financed by the billionaire couple John and Laura Arnold, who’ve spent millions backing other research and advocacy on drug pricing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am a cancer patient my drug last year started at $8000. Yes $8000. Now it is $11000.
    I know someone who worked for Bch/bs and the trips bonuses are what is driving our costs up. I’m with you

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy